Skip to main content
MedPathMedPath Home
Clinical Trials/ISRCTN13175485
ISRCTN13175485
Completed
Phase 1

A Phase Ia, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of single-ascending doses of RO7303509 in healthy volunteers

Genentech, Inc.0 sites57 target enrollmentAugust 20, 2020
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsInflammationSigns and Symptoms

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Inflammation
Sponsor
Genentech, Inc.
Enrollment
57
Status
Completed
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

2024 Results article in https://pubmed.ncbi.nlm.nih.gov/38662148/ (added 26/04/2024)

Registry
who.int
Start Date
August 20, 2020
End Date
May 19, 2022
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •1\. Age \=18 years and \=75 years
  • •2\. Ability to comply with the study protocol, in the investigator’s judgment
  • •3\. Use of contraceptive measures

Exclusion Criteria

  • •1\. Pregnant or breastfeeding, or intending to become pregnant during the study or within 85 days after the dose of RO7303509
  • •2\. No comorbid conditions that may interfere with the evaluation of an investigational medical product
  • •3\. No history or evidence of substance abuse that would pose a risk to participants safety, interfere with the conduct of the study, or have an impact on the study results
  • •4\. History of severe allergic or anaphylactic reactions to human, humanized, or Current treatment with medications that are well known to prolong the QT

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 1
A study to test the effect of experimental drugs EDP1815 and EDP2939 on skin inflammation in healthy volunteers after KLH and imiquimod challengeKLH and imiquimod induced skin inflammation in healthy volunteersSkin and Connective Tissue Diseases
ISRCTN29254828Evelo Biosciences38
Completed
Phase 1
A study to evaluate the safety, tolerability and processing by the body of RO7440688 in healthy volunteers
ISRCTN15492429Genentech, Inc67
Completed
Phase 3
A study to evaluate if different doses of KVD900 are safe and effective in treating attacks in patients with hereditary angioedemaHereditary angioedema (HAE) type I or type II.Haematological DisordersHereditary Angioedema Type I or II
ISRCTN14762022KalVista Pharmaceuticals Ltd136
Completed
N/A
Dietary food supplement Helinorm containing L.reuteri DSM 17648 in eradication treatment inH.pylori-positive patients with functional dyspepsia?onfirmed diagnosis of functional dyspepsia according to Rome IV criteria and presence of H. pylori infection according to 13C-UBTDigestive SystemFunctional dyspepsia
ISRCTN20716052izhny Novgorod Chemical and Pharmaceutical Plant Joint Stock Company (Nizhpharm JSC)172
Completed
Phase 1
Testing the safety and effects of a new drug (G3215) in adult subjectsDiabetes Mellitus ObesityNutritional, Metabolic, Endocrine
ISRCTN67889041Imperial College London24